Decitabine s.k. is indicated for treatment of patients with myelodysplastic syndromes (MDS) including previously treated and untreated, de novo and secondary MDS of all French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia) and Intermediate-1, Intermediate-2 and High-Risk International Prognostic Scoring System groups.
Decitabine s.k. is indicated for the treatment of adult patients with newly diagnosed de novo or secondary acute myeloid leukemia (AML), according to the World Health Organisation (WHO) classification, who are not candidates for standard induction chemotherapy.
RX
Decitabine S.K
**Disclaimer:
The images and designs presented on this website are for illustrative purposes only. Actual products may differ from those shown, including variations in color, packaging design, wording, or other visual features. The company assumes no responsibility for any such discrepancies and does not undertake to update the website to reflect changes in the actual product.
*** Disclaimer
The information provided herein is not intended as medical advice and must not be relied upon for diagnosis, treatment, or the provision of medical care. It does not replace the official prescribing/patient leaflet or consultation with a qualified healthcare professional. Before any use, always review the official physician/patient leaflet and consult a licensed physician. The company assumes no responsibility or liability for any reliance placed on the information presented on this page.
